Vienna, VA – Dr. Salwa A. Elgebaly, PhD is the Founder and CEO of Nour Heart, Inc., dedicated to the development of the new cardioprotective drug, Cyclocreatine Phosphate for patients with Ischemic Heart Diseases.

“I wanted to bring this to life for the people whose stories touched me,” says Dr. Elgebaly. “I believe in Cyclocreatine phosphate.”

Cyclocreatine phosphate could be used in end-stage heart failure patients scheduled for heart transplantation procedure and, thus, can increase donor utilization and patients’ outcomes. For the new heart transplantation procedures using “donation after circulatory death (DCD)” hearts, Cyclocreatine phosphate would be very effective in protecting donor hearts during the warm ischemic time, reducing heart dysfunction after the transplant.

CCrP can also be administered to heart attack patients in the pre-hospital phase, as well as during, or some hours after, the angioplasty procedure to potentially achieve protection of a greater amount of heart tissue, reduce scar size, and limit the progression of the heart attack to heart failure.

The FDA has awarded Cyclocreatine phosphate with its Orphan Drug Designation for its use as a Cardioprotective drug for end-stage heart failure patients scheduled for heart transplantation procedure. Interestingly, Cyclocreatine phosphate received the unique designation of: “Prevention of Ischemic Injury to Enhance Cardiac Graft Recovery and Survival in Heart Transplantation”.

For more information, visit www.nourheart.com

CUTV News Radio Dr. Salwa Ahmed Elgebaly of Nour Heart Inc.

Share

Embed